Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating azacitidine and chimerism in patients with myelodysplastic syndrome or acute myeloid leukemia after alloge…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML) [Phase 2]
This is a Phase 2 clinical trial evaluating azacitidine in combination with venetoclax for acute myeloid leukemia; the study is currently re…
-
CLINICAL_TRIALS withdrawal · 2026-02-24Clinical Trial Update: Cryopreserved MMUD BM With PTCy for Hematologic Malignancies [Phase 1]
Phase 1 trial of cryopreserved MMUD bone marrow with post-transplant cyclophosphamide for hematologic malignancies has been withdrawn.
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies [Phase 1]
This clinical trial update describes a Phase 1 study of Orca-Q for patients with hematologic malignancies undergoing allogeneic stem cell tr…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Venetoclax Combined With Azacitidine for Consolidation Therapy in AML [Phase 2]
A Phase 2 trial is evaluating the combination of Venetoclax and Azacitidine as consolidation therapy for Acute Myeloid Leukemia; the study i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: FLT3-ITD Targeted Therapy in Fit AML Patients [Phase 2, Phase 3]
An early-phase trial update on a FLT3-ITD targeted therapy for fit patients with acute myeloid leukemia, involving Phase 2 and Phase 3 studi…
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia [Phase 1]
Phase 1 trial combining uproleselan, azacitidine, and venetoclax in newly diagnosed acute myeloid leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: A Phase 1 Study of BMF-500 in Adults With Acute Leukemia [Phase 1]
A Phase 1 trial evaluating BMF-500 in adults with acute leukemia is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
A clinical trial update describing a real-world study on treatment experiences for breast, lung, ovarian cancer, multiple myeloma, and acute…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia [Phase 1]
A Phase 1 trial evaluating the safety and feasibility of a liposomal cytarabine, daunorubicin, and gemtuzumab ozogamicin combination in rela…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia [Phase 2]
A Phase 2 clinical trial evaluating liposome-encapsulated daunorubicin-cytarabine in combination with venetoclax for relapsed, refractory, o…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating liposome-encapsulated daunorubicin-cytarabine (CPX-351) in combination with gemtuzumab ozogamicin for relapsed or r…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT [NA]
Clinical trial update indicates ongoing recruitment for a study evaluating CD45RA-depleted peripheral stem cell addback to prevent viral or …
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia [Phase 2]
A Phase 2 clinical trial evaluating a combination of cladribine, low-dose cytarabine, and venetoclax for relapsed/refractory or secondary ac…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial
A trial-design study describing a Generative AI and propensity-score matching model for the VEN-DEC Phase II AML study in elderly patients e…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS [Phase 2, Phase 3]
A phase 2/3 clinical trial is investigating venetoclax in combination with a fractionated busulfan conditioning regimen for high-risk acute …
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia [Phase 1]
Phase 1 study evaluating CD371-YSNVZIL-18 CAR T cells for acute myeloid leukemia; the trial is currently recruiting and includes relapsed or…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) [Phase 1]
Phase 1 study evaluating rezatapopt in combination with azacitidine for TP53Y220C mutant myeloid malignancies (acute myeloid leukemia or mye…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial evaluating the combination of ASTX727, venetoclax, and gilteritinib for newly diagnosed, relapsed or refrac…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia [Phase 1]
This is a Phase 1 clinical trial evaluating the safety and preliminary efficacy of venetoclax combined with Vyxeos (CPX-351) in patients wit…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) [Phase 1]
This Phase 1 open-label pediatric study aims to determine the recommended dose and evaluate pharmacokinetics, pharmacodynamics, safety, and …
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A pharmacokinetic study is evaluating how crushing venetoclax tablets and dissolving them in solution affects drug exposure, to assess alter…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]
A Phase 1 trial update evaluating the combination of nivolumab and ipilimumab after donor stem cell transplantation in patients with high-ri…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias [Phase 1]
A Phase 1 clinical trial update reports that SNDX-5613 is being studied in combination with intensive chemotherapy for acute myeloid leukemi…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia [Phase 1]
Phase 1/1b trial of olutasidenib and ziftomenib for NPM1 and IDH1 co-mutated acute myeloid leukemia is currently not yet recruiting.